ArticleThe Lancet. Oncology2020
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.
Federica Tomao et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this paperpooled itcites it